Modeling and Simulation Archives

On-Demand Webinar

Machine Learning for Population PK Model Selection: Theory and Practice

Three of Certara's expert modelers provide a gentle introduction to machine learning in our field.…

CertaraFebruary 7, 2025

On-Demand Webinar

Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling

With the release of Version 24, the Simcyp Simulator introduces cutting-edge enhancements that further elevate…

CertaraFebruary 7, 2025

Publication

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…

CertaraFebruary 6, 2025

Publication

Understanding Variability in CAR-T Cell Therapy Kinetics

Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…

CertaraJanuary 23, 2025

On-Demand Webinar

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…

CertaraJanuary 9, 2025

Press Coverage

AI in Life Sciences Finds an Early Success and Will Continue in 2025

Fran Brown highlights how AI in life sciences drives more precise drug development and reduces…

CertaraDecember 24, 2024

Poster

Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA

CertaraDecember 11, 2024

Video

Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development

At the 2024 AAPS PharmSci 360 conference, Bioanalysis Zone interviewed Piet van der Graaf, Senior…

CertaraDecember 10, 2024

Publication

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…

CertaraDecember 9, 2024

Poster

Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi

CertaraNovember 22, 2024

Modeling and Simulation

Machine Learning for Population PK Model Selection: Theory and Practice

Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

Understanding Variability in CAR-T Cell Therapy Kinetics

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

AI in Life Sciences Finds an Early Success and Will Continue in 2025

Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA

Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi

Newsletter sign up

Quick links

Solutions

Contact